Advertisement

Drug Safety

, Volume 39, Issue 4, pp 307–321 | Cite as

Risk of Seizures Associated with Antidepressant Use in Patients with Depressive Disorder: Follow-up Study with a Nested Case–Control Analysis Using the Clinical Practice Research Datalink

  • Marlene Bloechliger
  • Alessandro Ceschi
  • Stephan Rüegg
  • Hugo Kupferschmidt
  • Stephan Kraehenbuehl
  • Susan S. Jick
  • Christoph R. Meier
  • Michael Bodmer
Original Research Article

Abstract

Introduction

Antidepressant use has been associated with an increased risk of seizures. Evidence on the association between antidepressant use at therapeutic doses and seizures mainly comes from clinical trials that were not designed to investigate this potential relationship.

Objective

The objective of this study was to assess the risk of first-time seizures in association with exposure to antidepressants in patients with depressive disorders.

Methods

We conducted a retrospective follow-up study with a nested case–control analysis between 1998 and 2012, using data from the UK-based Clinical Practice Research Datalink (CPRD). We estimated crude incidence rates with 95 % confidence intervals (CIs) of seizures in depressed patients who used selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), ‘other antidepressants’, no antidepressants, or who had used antidepressants in the past. To adjust for potential confounding, we estimated odds ratios of antidepressant drug use among cases with seizures and matched controls in a nested case–control analysis.

Results

Of 151,005 depressed patients, 619 had an incident seizure during follow-up. Incidence rates per 10,000 person-years were 12.44 (95 % CI 10.67–14.21) in SSRI users, 15.44 (95 % CI 8.99–21.89) in SNRI users, 8.33 (95 % CI 4.68–11.98) in TCA users, 9.33 (95 % CI 6.19–12.46) in non-users of antidepressants, and 5.05 (95 % CI 4.49–5.62) in past users of antidepressants. In the case–control analysis, relative risk estimates for seizures were increased in current users of SSRIs (adjusted odds ratio 1.98, 95 % CI 1.48–2.66) and SNRIs (adjusted odds ratio 1.99, 95 % CI 1.20–3.29), but not TCAs (adjusted odds ratio 0.99, 95 % CI 0.63–1.53), compared with non-users.

Conclusion

Current use of SSRIs or SNRIs was associated with a twofold increased risk of first-time seizures compared with non-use, while current use of TCAs (mostly low dose) was not associated with seizures. Treatment initiation in SSRI and SNRI users was associated with a higher risk of seizures than longer-term treatment.

Keywords

Depressed Patient Venlafaxine Index Date Duloxetine Mirtazapine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We thank Pascal Egger (Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland) for the programming and technical support.

Compliance with Ethical Standards

Funding

No sources of funding were used to assist in the preparation of this study.

Conflict of interest

Marlene Bloechliger, Alessandro Ceschi, Stephan Rueegg, Hugo Kupferschmidt, Stephan Kraehenbuehl, Susan S. Jick, Christoph R. Meier, and Michael Bodmer have no conflicts of interest that are directly related to the content of this study.

Authors’ contributions

Study conception and design: Marlene Bloechliger, Alessandro Ceschi, Stephan Rueegg, Hugo Kupferschmidt, Stephan Kraehenbuehl, Susan S. Jick, Christoph R. Meier, and Michael Bodmer. Acquisition of data, guarantors for the study: Susan S. Jick and Christoph R. Meier. Analysis and interpretation of data: Marlene Bloechliger, Christoph R. Meier, Michael Bodmer. Drafting the manuscript: Marlene Bloechliger. Editing the manuscript: Alessandro Ceschi, Stephan Rueegg, Hugo Kupferschmidt, Stephan Kraehenbuehl, Susan S. Jick, Christoph R. Meier, and Michael Bodmer.

Supplementary material

40264_2015_363_MOESM1_ESM.pdf (384 kb)
Supplementary material 1 (PDF 385 kb)

References

  1. 1.
    World Health Organization (WHO). Disease burden. Regional estimates for 2000–2011. 2013. http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index1.html. Accessed 18 Mar 2014.
  2. 2.
    Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. PLoS One. 2013;8:e75362.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    National Institute for Health and Care Excellence (NICE). Depression in adults: recognition and management. NICE guidance CG90. 2009. http://guidance.nice.org.uk/CG90/NICEGuidance/pdf/English. Accessed 24 Mar 2014.
  4. 4.
    Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14:334–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Judge BS, Rentmeester LL. Antidepressant overdose-induced seizures. Psychiatr Clin North Am. 2013;36:245–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25:91–110.CrossRefPubMedGoogle Scholar
  7. 7.
    Reichert C, Reichert P, Monnet-Tschudi F, Kupferschmidt H, Ceschi A, Rauber-Lüthy C. Seizures after single-agent overdose with pharmaceutical drugs: analysis of cases reported to a poison center. Clin Toxicol (Phila). 2014;52:629–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;62:345–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Block F, Dafotakis M. Drug-induced seizures [in German]. Fortschr Neurol Psychiatr. 2013;81:28–34.PubMedGoogle Scholar
  10. 10.
    Steinert T, Baier H, Fröscher W, Jandl M. Epileptic seizures during treatment with antidepressants and neuroleptics [in German]. Fortschr Neurol Psychiatr. 2011;79:138–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract. 2005;59:1435–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Köster M, Grohmann R, Engel RR, Nitsche MA, Rüther E, Degner D. Seizures during antidepressant treatment in psychiatric inpatients—results from the transnational pharmacovigilance project “Arzneimittelsicherheit in der Psychiatrie” (AMSP) 1993–2008. Psychopharmacology (Berl). 2013;230:191–201.CrossRefPubMedGoogle Scholar
  13. 13.
    Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf. 2008;31:851–65.CrossRefPubMedGoogle Scholar
  15. 15.
    The Clinical Practice Research Datalink (CPRD). 2014. http://www.cprd.com. Accessed 9 Apr 2014.
  16. 16.
    Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012;3:89–99.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60:e128–36.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69:4–14.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Reed C, Hong J, Novick D, Lenox-Smith A, Happich M. Health care costs before and after diagnosis of depression in patients with unexplained pain: a retrospective cohort study using the United Kingdom General Practice Research Database. Clinicoecon. Outcomes Res. 2013;5:37–47.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891–5.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case–control study. BMJ. 2005;330:389.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf. 2004;27:203–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Jick SS, Jick H, Knauss TA, Dean AD. Antidepressants and convulsions. J Clin Psychopharmacol. 1992;12:241–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Seizures in patients with Alzheimer’s disease or vascular dementia: a population-based nested case–control analysis. Epilepsia. 2013;54:700–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Martinez C, Sullivan T, Hauser WA. Prevalence of acute repetitive seizures (ARS) in the United Kingdom. Epilepsy Res. 2009;87:137–43.CrossRefPubMedGoogle Scholar
  26. 26.
    Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy. 2000;20:629–34.CrossRefPubMedGoogle Scholar
  27. 27.
    Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke. 2004;35:1769–75.CrossRefPubMedGoogle Scholar
  28. 28.
    World Health Organization WHO. ATC/DDD Index 2014. 2014. http://www.whocc.no/atc_ddd_index/. Accessed 31 Mar 2014.
  29. 29.
    Schulz KF, Grimes DA. Case–control studies: research in reverse. Lancet. 2002;359:431–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Wilden JA, Cohen-Gadol AA. Evaluation of first nonfebrile seizures. Am Fam Physician. 2012;86:334–40.PubMedGoogle Scholar
  31. 31.
    Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol. 2006;59:35–41.CrossRefPubMedGoogle Scholar
  32. 32.
    Saragoussi D, Chollet J, Bineau S, Chalem Y, Milea D. Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) study. Int J Clin Pract. 2012;66:1079–87.CrossRefPubMedGoogle Scholar
  33. 33.
    Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol. 2005;4:627–34.CrossRefPubMedGoogle Scholar
  34. 34.
    Kotsopoulos IAW, van Merode T, Kessels FGH, de Krom MCTFM, Knottnerus JA. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia. 2002;43:1402–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol. 2000;47:246–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72:184–91.CrossRefPubMedGoogle Scholar
  37. 37.
    Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol. 2012;11:1093–102.CrossRefPubMedGoogle Scholar
  38. 38.
    Furukawa TA, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev. 2003;(3):CD003197. doi: 10.1002/14651858.CD003197
  39. 39.
    Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ. 2014;348:g254.CrossRefPubMedGoogle Scholar
  40. 40.
    Cardamone L, Salzberg MR, O’Brien TJ, Jones NC. Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol. 2013;168:1531–54.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Salzberg M. Neurobiological links between epilepsy and mood disorders. Neurol Asia. 2011;16(Suppl 1):37–40.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Marlene Bloechliger
    • 1
  • Alessandro Ceschi
    • 2
    • 3
  • Stephan Rüegg
    • 4
  • Hugo Kupferschmidt
    • 2
  • Stephan Kraehenbuehl
    • 5
  • Susan S. Jick
    • 6
  • Christoph R. Meier
    • 1
    • 6
    • 7
  • Michael Bodmer
    • 1
    • 8
  1. 1.Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, Basel Pharmacoepidemiology UnitUniversity of BaselBaselSwitzerland
  2. 2.National Poisons Centre, Tox Info SuisseAssociated Institute of the University of ZurichZurichSwitzerland
  3. 3.Division of Clinical Pharmacology and Toxicology, Department of Internal MedicineEnte Ospedaliero Cantonale LuganoLuganoSwitzerland
  4. 4.Division of Clinical Neurophysiology, Department of NeurologyUniversity Hospital BaselBaselSwitzerland
  5. 5.Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical SciencesUniversity of BaselBaselSwitzerland
  6. 6.Boston Collaborative Drug Surveillance ProgramBoston University School of Public HealthLexingtonUSA
  7. 7.Hospital PharmacyUniversity Hospital BaselBaselSwitzerland
  8. 8.Medical DepartmentZuger KantonsspitalZugSwitzerland

Personalised recommendations